1.Preclinical Study of Novel Curcumin Analogue SSC-5 Using Orthotopic Tumor Xenograft Model for Esophageal Squamous Cell Carcinoma.
Lai Nar TUNG ; Senchuan SONG ; Kin Tak CHAN ; Mei Yuk CHOI ; Ho Yu LAM ; Chung Man CHAN ; Zhiyong CHEN ; Hector K. WANG ; Hoi Ting LEUNG ; Simon LAW ; Yanmin HUANG ; Huacan SONG ; Nikki P. LEE
Cancer Research and Treatment 2018;50(4):1362-1377
PURPOSE: Tumor xenograft model is an indispensable animal cancer model. In esophageal squamous cell carcinoma (ESCC) research, orthotopic tumor xenograft model establishes tumor xenograft in the animal esophagus, which allows the study of tumorigenesis in its native microenvironment. MATERIALS AND METHODS: In this study,we described two simple and reproducible methods to develop tumor xenograft at the cervical or the abdominal esophagus in nude mice by direct injection of ESCC cells in the esophageal wall. RESULTS: In comparing these two methods, the cervical one presented with more clinically relevant features, i.e., esophageal stricture, body weight loss and poor survival. In addition, the derived tumor xenografts accompanied a rapid growth rate and a high tendency to invade into the surrounding structures. This model was subsequently used to study the anti-tumor effect of curcumin, which is known for its potential therapeutic effects in various diseases including cancers, and its analogue SSC-5. SSC-5 was selected among the eight newly synthesized curcumin analogues based on its superior anti-tumor effect demonstrated in an MTT cell proliferation assay and its effects on apoptosis induction and cell cycle arrest in cultured ESCC cells. Treatment of orthotopic tumor-bearing mice with SSC-5 resulted in an inhibition in tumor growth and invasion. CONCLUSION: Taken together, we have established a clinically relevant orthotopic tumor xenograft model that can serve as a preclinical tool for screening new anti-tumor compounds, e.g., SSC-5, in ESCC.
Animals
;
Apoptosis
;
Body Weight
;
Carcinogenesis
;
Carcinoma, Squamous Cell*
;
Cell Cycle Checkpoints
;
Cell Proliferation
;
Curcumin*
;
Epithelial Cells*
;
Esophageal Stenosis
;
Esophagus
;
Heterografts*
;
Mass Screening
;
Mice
;
Mice, Nude
;
Therapeutic Uses
2.Outcomes of radical prostatectomy in a 20-year localized prostate cancer single institution series in China.
Xiao-Hao RUAN ; Tsun Tsun STACIA CHUN ; Da HUANG ; Hoi-Lung WONG ; Brian Sze-Ho HO ; Chiu-Fung TSANG ; Terence Chun-Ting LAI ; Ada Tsui-Lin NG ; Rong NA ; James Hok-Leung TSU
Asian Journal of Andrology 2023;25(3):345-349
The long-term survival outcomes of radical prostatectomy (RP) in Chinese prostate cancer (PCa) patients are poorly understood. We conducted a single-center, retrospective analysis of patients undergoing RP to study the prognostic value of pathological and surgical information. From April 1998 to February 2022, 782 patients undergoing RP at Queen Mary Hospital of The University of Hong Kong (Hong Kong, China) were included in our study. Multivariable Cox regression analysis and Kaplan-Meier analysis with stratification were performed. The 5-year, 10-year, and 15-year overall survival (OS) rates were 96.6%, 86.8%, and 70.6%, respectively, while the 5-year, 10-year, and 15-year PCa-specific survival (PSS) rates were 99.7%, 98.6%, and 97.8%, respectively. Surgical International Society of Urological Pathology PCa grades (ISUP Grade Group) ≥4 was significantly associated with poorer PSS (hazard ratio [HR] = 8.52, 95% confidence interval [CI]: 1.42-51.25, P = 0.02). Pathological T3 stage was not significantly associated with PSS or OS in our cohort. Lymph node invasion and extracapsular extension might be associated with worse PSS (HR = 20.30, 95% CI: 1.22-336.38, P = 0.04; and HR = 7.29, 95% CI: 1.22-43.64, P = 0.03, respectively). Different surgical approaches (open, laparoscopic, or robotic-assisted) had similar outcomes in terms of PSS and OS. In conclusion, we report the longest timespan follow-up of Chinese PCa patients after RP with different approaches.
Male
;
Humans
;
Retrospective Studies
;
Prostatic Neoplasms/pathology*
;
Prostate/pathology*
;
Prostatectomy
;
Prognosis
;
Neoplasm Grading